Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
175.66(c) 181.32(c) 177.65(c) 185.45(c) 185.48 Last
2 395 236 1 257 515 1 064 193 1 136 652 827 326 Volume
-0.44% +3.22% -2.02% +4.39% +0.02% Change
More quotes
Financials (USD)
Sales 2018 3 005 M
EBIT 2018 1 045 M
Net income 2018 790 M
Finance 2018 2 667 M
Yield 2018 -
Sales 2019 3 552 M
EBIT 2019 1 334 M
Net income 2019 890 M
Finance 2019 3 746 M
Yield 2019 -
P/E ratio 2018 60,39
P/E ratio 2019 55,11
EV / Sales2018 14,5x
EV / Sales2019 12,0x
Capitalization 46 338 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
10/16VERTEX PHARMACEUTICALS : to Announce Third Quarter 2018 Financial Results on Oct..
BU
10/12VERTEX PHARMACEUTICALS : FDA lifts hold on IND for CRISPR's sickle cell trial
AQ
10/11VERTEX PHARMACEUTICALS : CRISPR Therapeutics and Vertex Announce FDA Has Lifted ..
AQ
10/01VERTEX PHARMACEUTICALS : Announces Access Contract in Denmark for Current and Fu..
BU
09/20NICE wavers on end of life exception for DLBCL CAR Ts, says Kymriah doesn't m..
AQ
09/13VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Healthcare Conference ..
AQ
09/12VERTEX PHARMACEUTICALS : Appoints Katharine Jensen as Head of Corporate Social R..
AQ
09/11VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Healthcare Conference ..
BU
09/10VERTEX PHARMACEUTICALS : Appoints Katharine Jensen as Head of Corporate Social R..
BU
09/10VERTEX PHARMACEUTICALS : Completes Enrollment of Two Phase 3 Studies of VX-659 i..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/17Insider Selling: Vertex Pharmaceuticals Incorporated $VRTX EVP Sells 2,125 Sh.. 
10/161/2 Monday Club was best known for its support for "repatriation" (i.e. depor..
2
10/16$AAPL $AMGN $AMZN $BIIB $BRK.B $CELG $GE $GILD $GOOGL $GS $INTC $JPM $M $MS $.. 
10/16Leerink Swann Raises Vertex Pharmaceuticals Q3 2018 Earnings Estimates to $0... 
10/15A cost effectiveness watchdog may charge drug makers for 'early scientific ad.. 
More tweets
Qtime:177
News from SeekingAlpha
10/17BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Roche's Deal, AcelRX Panel Vote, Crispr A.. 
10/15FDA issues new guidance aimed at more efficient drug development 
10/14LONG-TERM OUTLOOK FOR VERTEX PHARMAC : October 13, 2018 
10/11The October Pause That Refreshes 
10/10FDA lifts clinical hold on CRISPR Therapeutics' gene therapy CTX001; shares u.. 
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 198 $
Spread / Average Target 6,9%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian Frederick Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS20.99%46 338
GILEAD SCIENCES1.59%95 398
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671
GENMAB-11.78%8 632